Document:

EX-10.11

 Exhibit 10.11 

 
  

Employment Agreement 
 Dated as of 17 June, 2021 

by and between 
  

					
	  

	Monte Rosa Therapeutics AG	  		  	(the Company)
	Aeschenvorstadt 36, 4051 Basel, Switzerland	  	

 and 

					
	  

	Dr. John Castle	  		  	(the Executive)
	Rudolf-Diesel-Strasse 40, 55131 Mainz, Germany	  	

 (The Company and the Executive are also referred to as Party or Parties) 

  
 1 of 15 

 Employment Agreement 

 

  

Employment Agreement 
  

 
 Preamble 

 

	A.	 The Executive and the Company have entered into an employment relationship on 2 June, 2021 pursuant to an
employment agreement dated 31 January, 2021 (the Prior Agreement). 

  

	B.	 With regard to the public offering of the Company’s equity securities, the Company has come to the
conclusion to revise and renew the previous agreements with its Executives. 

  

	C.	 The Company desires to continue to employ the Executive and the Executive desires to continue to be employed by
the Company on the new terms and conditions. 

  

	D.	 Therefore, the Parties enter into the following new employment agreement (the Employment Agreement),
which replaces all previous agreements between the Parties: 

  

 

	1.	 Commencement Date 

This Employment Agreement with the Executive starts as of the closing of the Company’s first underwritten public offering of its equity
securities pursuant to an effective registration statement under the Securities Act of 1933 (the Commencement Date). It shall be concluded for an indefinite period. 
  

 

	2.	 Position 

  

	2.1.	 Function 

The Executive shall serve as the Chief Data Scientist of the Company and shall have such powers and duties as may from time to time be
prescribed by the Chief Executive Officer (the CEO) or other duly authorized executive. The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. The Executive shall be working
100 %. 

  
 2 of 15 

 Employment Agreement 

 

	2.2.	 Group Structure 

The Executive acknowledges that the Company is part of a group of companies ultimately controlled by Monte Rosa Therapeutics, Inc. (each such
company including the holding company a Group Company). The Executive acknowledges that the Executive will need to work with and/or report to other employees and/or officers of other Group Companies. 

 

	2.3.	 Work for Third Parties 

The Executive is not entitled to work for any third party or to engage in any gainful employment without the preceding written approval of the
Company. 
  

	2.4.	 Conflict of Interests 

The Executive shall avoid any conflict of interest and inform the Company immediately if any potential conflict of interest arises. 

A conflict of interest arises especially in case of a participation in suppliers or clients of the Company or in a Group Company. 

 
  

	3.	 Place of Work 

The Executive’s principal place of work shall presently be at the premises of the Employer at Technologiepark Basel, Hochbergerstrasse
60C, 4057 Basel, Switzerland. 
 Nevertheless, the Executive understands and agrees that the Executive may, in the course of the Employment
and where reasonably requested by the Company, be required to travel to and work in other places and countries. 
  

 

	4.	 Compensation 

 

	4.1.	 Base Salary 

The Executive shall receive an annual base salary of CHF 294,972 gross (the Base Salary), payable in twelve monthly instalments of CHF
24,581 gross each at the end of the month, plus any mandatory contributions for family and children allowances. 

  
 3 of 15 

 Employment Agreement 

 

	4.2.	 Relocation / Travel 

The Employee will be reimbursed, within the first 12 months, for relocation and / or travel expenses up to a maximum of CHF20,000 (twenty
thousand CHF) as evidenced by written receipt(s). 
  

	4.3.	 Bonus 

The Executive shall be entitled to a target annual bonus payment of 35% of the base salary. Pay-out of
this bonus will be at the full discretion of the Board of Directors of the Company (the Board) or the Compensation Committee of the Board (the Compensation Committee). 

Legally, the bonus constitutes a real gratuity (“echte Gratifikation”) within the meaning of Art. 322d of the Swiss Code of
Obligations. It is therefore neither a salary component in whole or in part nor otherwise contractually owed. In any case, the Executive must be employed by the Company on the day such bonus would become due. No bonus payment can be used to derive
any individual legal claims to (future) bonus payments, neither in principle nor in terms of amount. This applies even if the Company makes bonus payments for several years and without an explicit reservation of voluntariness. 

 

	4.4.	 Deductions 

From the salary (as defined by the applicable laws and regulations, which may include bonuses, allowances, participations and further
Additional Payments) any portions of Executive’s social security contributions (AHV (Old-age and surviving dependents insurance)/IV (Disability insurance)/EO (Wage compensation), ALV (Unemployment
insurance), UV (Accidence insurance), KTG (daily allowance insurance), premiums to pension schemes (cp. Regulations of the pension fund) and withholding taxes, if any, will be deducted and withheld by the Company from the payments made to the
Executive. 
  
  

	5.	 Expenses 

The Executive shall be entitled to reimbursement by the Company of
out-of-pocket business expenses reasonably incurred by the Executive during the Employment in the performance of the Executive’s duties under this Employment
Agreement. However, the reimbursement is subject to (i) the submission of relevant vouchers and receipts and (ii) the compliance with the reimbursement policies of the Company possibly established and amended from time to time. 

  
 4 of 15 

 Employment Agreement 

 

  

	6.	 Participation Plan 

The Executive may be given the opportunity by the Company or a Group Company to participate in the growth of the Employer or a Group Company
(the Participation) pursuant to a participation plan such as, for instance, an employee share option plan or a share plan, and as amended from time to time (the Participation Plan). It is in the full discretion of the Company or the
Group Company issuing such Participation Plan to issue and/or to amend such Participation Plan at any time. 
  

 

	7.	 Termination 

A notice period of 3 months shall be effective (as per the end of each month). 

The Employment is being terminated automatically at the end of the month in which the Executive reaches the retirement age according to the
federal law of old-age and surviving dependents insurance (AHVG). In case of a permanent disability to work the same applies. In case of a partial permanent disability the Employment ends to the same extent as
the Executive is declared disabled. 
 As soon as this employment agreement has been terminated or as agreed with the Employer, the Executive
is deemed to resign with immediate effect from all other positions held with the Company, any of its Subsidiaries and its Affiliates. 
  

 

	8.	 Severance Payment 

The severance payment depends on whether the termination takes place on or within or after 12 months since a change in control. Change in
Control shall mean a Sale Event as defined in the Company’s 2021 Stock Option and Incentive Plan (as the same may be amended from time to time) (the Change in Control). 

 

	8.1.	 Termination outside the Change in Control Period 

Without any Change of Control or after 12 months since the Change of Control, the Company shall pay the Executive an amount equal to six
(6) months of the Executive’s Base Salary (the Severance Amount). 
  

	8.2.	 Termination within the Change in Control Period 

If the Termination of the Employment Agreement is on or within 12 months of such Change in Control (the Change in Control Period) and
subject to the conditions set out in 8.2.1 and 8.2.2 hereafter, the Company shall pay the Executive a 

  
 5 of 15 

 Employment Agreement 

 

 
lump sum in cash in an amount equal to the sum of (A) nine (9) months of the Executive’s then-current Base Salary (or the Executive’s Base Salary in effect immediately prior
to the Change in Control, if higher) plus (B) 0.75 times the Executive’s Target Bonus for the then-current year (or the Executive’s Target Bonus in effect immediately prior to the Change in Control, if higher) (the Change in Control
Payment). 
 The amounts payable under this Section 8.2 shall be paid or commence to be paid within 60 days after the Date of
Termination. 
  

	8.2.1.	 Termination by the Employer 

In case the Employment Agreement has been terminated by the Employer, clause 8.2 shall only apply if the termination was not due to 

 

	 	•	 	 the Executive’s willful misconduct in connection with the performance of the Executive’s duties,
including, without limitation, misappropriation of funds or property of the Company other than the occasional, customary and de minimis use of Company property for personal purposes; 

 

	 	•	 	 the Executive’s commission of acts satisfying the elements of (A) any felony or (B) a misdemeanor
involving moral turpitude, deceit, dishonesty, fraud or conduct by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company if the Executive was retained in the Executive’s position;

  

	 	•	 	 the Executive’s continued non-performance of the Executive’s
duties that has continued for more than 15 days following written notice of such non-performance; 

  

	 	•	 	 a material breach by the Executive of the Restrictive Covenants Agreement or any other confidentiality,
assignment, noncompetition and/or nonsolicitation obligations; 

  

	 	•	 	 a material violation by the Executive of the Company’s lawful written employment policies;

  

	 	•	 	 the Executive’s diversion of any business or business opportunity of the Company for the benefit of any
party other than the Company without the consent of the Company; or 

  
 6 of 15 

 Employment Agreement 

 

	 	•	 	 the Executive’s failure to cooperate with an internal investigation or an investigation by regulatory or law
enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate
or to produce documents or other materials in connection with such investigation. 

  

	8.2.2.	 Termination by the Executive 

In case the Employment Agreement has been terminated by the Executive, clause 8.2 shall only apply if the termination was due to 

 

	 	•	 	 a material diminution in the Executive’s responsibilities, authority or duties; 

 

	 	•	 	 a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company; 

 

	 	•	 	 a material change in the geographic location of the principal office of the Company to which the Executive is
assigned, such that there is an increase of at least fifty (50) miles of driving distance to such location from the Executive’s principal residence as of such change; or 

 

	 	•	 	 a material breach of this Agreement by the Company; 

and 
  

	 	•	 	 the Executive reasonably determines in good faith; 

 

	 	•	 	 the Executive notifies the Company in writing of such reason within 60 days of the first occurrence;

  

	 	•	 	 the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days
following such notice (the Cure Period), to remedy the reason for termination; 

  

	 	•	 	 notwithstanding such efforts, the reason for termination continues to exist at the end of the Cure Period; and

  

	 	•	 	 the Executive terminates the Employment Agreement within 60 days after the end of the Cure Period.

  
 7 of 15 

 Employment Agreement 

 

  

	9.	 Working Time 

 

	9.1.	 General 

The expected weekly working time of the Executive is 40 hours per week based on a 100% position). 

 

	9.2.	 Overtime and Extra Hours 

The Executive shall work extra hours and overtime and extra hours, if ordered or necessary for business and to the extent such work can
reasonably be expected from the Executive in good faith. 
 The Base Salary as defined in Section 4.1 includes any and all remuneration
for such overtime and extra hours, and the Executive shall have no entitlement to additional compensation for such overtime and/or extra hours, whether in cash or in kind. 

If any additional compensation for overtime or excess hours work should ever become due based on any legal provisions, the Executive agrees
that the Company can offset any bonus as per Section 4.2 as well as any other compensation in addition to the Base Salary, such as e.g. any gain resulting from equity based compensation (such as options, shares, phantom shares, etc.) granted
during Employment, from such overtime/excess hours compensation. 
  
  

	10.	 Vacation 

The Executive is entitled to 22 business days of vacation per calendar year (based on 100% employment). For part time employment, this amount
shall be calculated pro rata temporis. 
 Vacation, company holidays and paid absences are further detailed in our Internal Guidelines. These
Guidelines can be amended from time to time. 
  
  

	11.	 Illness, Paternity, Accident and Death 

 

	11.1.	 Medical Certificate 

If the Executive’s absence exceeds three business days, the Executive shall, without request by the Company furnish a medical certificate.
However, the Company reserves the right to demand for a medical certificate in case of any absence, irrespective of the length of the absence. The Company is entitled to ask the Executive to consult a medical examiner at the Company’s expense.

  
 8 of 15 

 Employment Agreement 

 

	11.2.	 Daily Allowance Insurance 

The Company concluded a collective daily allowance which covers temporary work incapacity due to illness. The insurance benefits replace the
statutory duty of the Company to continue to pay the Executive’s salary. 
 If an Executive is prevented from performing the
Executive’s duties arising out of or relating to the Employment due to illness, then the Company will continue to pay the base salary pursuant to the collective daily allowance insurance (Krankentaggeldversicherung) of the Company,
provided that the conditions of the collective daily allowance insurance are being met and that the Executive complies with the conditions of the collective daily allowance insurance and with the directives of the Company. In principle, the daily
allowance insurance provides for the following coverage: After a waiting period of 30 days, 80 % of the Base Salary up to CHF 400’000.– during up to 730 days. During the waiting period of 30 days 100% of the Base Salary according to
Section 5.1. is paid to the Executive. 
 After the waiting period, the Executive is not entitled to any remuneration (including his
salary, bonus, flat expenses or private use of the company car, etc.) in addition to the insurance benefits. 
 The insurance premium for the
daily allowance insurance is paid by the Company. 
  

	11.3.	 Paternity 

The Executive’s entitlement in the event of paternity is governed by the Federal law of wage compensation (EOG). 

 

	11.4.	 Occupational and Non-occupational Accidents

 During the Employment the Executive is insured for occupational and
non-occupational accidents. Premiums for occupational accident insurance and occupational sickness insurance are paid by the Company. Premiums for non-occupational
accident insurance are paid by the Executive. 
  
  

	12.	 Pension Plan 

The Executive will enter into the Company Pension Plan into which both Executive and Employer will pay contributions as specified. The plan can
be amended from time to time. 

  
 9 of 15 

 Employment Agreement 

 

  

	13.	 Intellectual Property Rights and work results 

The Company is entitled to all work results and intellectual property (including, but not limited to inventions, designs and copyrights)
created by the Executive in the course of the Employment and in performance of his contractual obligations, as well as all work results and intellectual property with the exception of inventions and designs created in the course of or in connection
with the Employment, but outside of the accomplishment of a contractual duty (notwithstanding whether individually or with the assistance of any other individuals/employees or legal entities). All such intellectual property and work results vest
irrevocably in the Company. The transfer of these intellectual property rights includes, amongst others, especially the copyrights on the works created by the Executive and therewith all rights mentioned in the articles 9 until 11 of the Swiss
Copyright Act. This transfer and assignment of work results and intellectual property is worldwide, unlimited in time, unrestricted in scope and encompasses all rights and exploitations, whether currently known or arising in the future. 

If any rights related to the work results and/or to intellectual property are not transferred by law, the Executive is obliged to transfer and
assign and hereby transfers and hereby assigns said rights to the Company. To the extent certain jurisdictions do not provide for the assignability of work results or intellectual property and related rights, the Executive hereby grants to the
Company an exclusive, worldwide, transferable, unlimited in time, irrevocable, sublicensable, fully paid-up and unrestricted license to in particular, without limitation, reproduce, make and have made, sell
and offer to sell, import, export, carry in transit, manufacture, store, place on market, modify, develop, transfer, distribute, display publicly, broadcast, retransmit, perform and exploit such work results, intellectual property and related
rights. 
 Compensation for the transfer said rights, in particular intellectual property rights or their licensing, respectively, is
included in the Base Salary according to Section 4.1 The transfer of right, resp. the granting of rights of use also comprises work results and intellectual property rights which will be created in the future and concerns also future and not
yet known rights of use. The Company especially acquires the right to change, revise or translate. The Executive especially waives his right to exercise any moral rights, to be mentioned as inventor or originator or to object to any first
publication, change, modification or translation. 
 If any invention or design is created in the course of or in connection with the
Employment, but outside of the accomplishment of a contractual duty, the Executive shall promptly inform the Company in writing. The Company hereby re 

  
 10 of 15 

 Employment Agreement 

 

 
serves title and ownership over such inventions and designs and commits to inform the Executive within six (6) months of its intent to acquire such ownership and title or to renounce to this
prerogative. If the Company chooses to acquire the title and ownership over such invention or design, it shall compensate the Executive adequately. If the Company, at its sole discretion, expressly renounces its prerogatives hereunder, then the
Executive shall own all rights, title and interest in and to such work results or intellectual property rights. 
  

 

	14.	 Data Protection and Data Transfer 

The Company will only process personal data of the Executive as reasonably required in relation with Executive’s suitability for the
employment relationship or for the execution and performance of the Employment and the obligations resulting therefrom, or if the Employer is required to do so by law. We may also transfer personal data to Group Companies and other third parties
within and outside of Switzerland, as explained further in the employee privacy notice. 
  

 

	15.	 Non-Competition and
Non-Solicitation 

  

	15.1.	 Non-Competition 

The Executive agrees that for a period of one year after termination of the Employment he will neither: 

 

	 	•	 	 directly or indirectly, once, occasionally or professionally, under the Executive’s name or under a third
party name, on behalf of his own or on behalf of third parties account compete with the Company or a Group Company; nor 

  

	 	•	 	 engage in any way in any enterprise competing with the Company or a Group Company, and the Executive also agrees
not to found, assist or promote any business being active in the same line of business as the Company or another Group Company. 

Particularly, any small molecular glue activity shall be considered as competing activity. Currently, especially C4, Kymera, Nurix, Arvinas and
other companies with similar focus are considered enterprises competing with the Company or a Group Company. 
 This non-compete obligation shall apply to the whole territory for which the Executive was responsible for during the Employment and/or to the whole territory in which the Executive was working with products of the
Company or a Group Company during the Employment, but at least to the territory of Switzerland and the Swiss market. 

  
 11 of 15 

 Employment Agreement 

 

	15.2.	 Non-Solicitation 

For a period of one year after termination of the Employment the Executive shall abstain directly or indirectly from: 

 

	 	(i)	 enticing away, soliciting or interfering with any personnel from the Company or another Group Company with whom
the Executive was in contact during his Employment; or 

  

	 	(ii)	 enticing away, soliciting or interfering with clients or contacts of the Company or another Group Company with
whom the Executive had contact during the last three years prior to the termination of the Employment or about whom he gained knowledge during the Employment relationship. 

 
  

	16.	 Confidentiality 

The Executive will have access to confidential and proprietary information relating to the business and operations of the Company, other Group
Companies and their clients. Such confidential and proprietary information constitutes a unique and valuable asset of the Company and other Group Companies and their acquisition required great time and expense. The disclosure or any other use of
such confidential or proprietary information, other than for the sole benefit of the Company or another Group Company, would be wrongful and would cause irreparable harm to the Company. 

The Executive is under a strict duty to keep all confidential and proprietary information strictly and permanently confidential and,
accordingly, shall not use during the Employment or after termination of the Employment directly or indirectly for any purpose other than for the sole benefit of the Company or another Group Company, or disclose or permit to be disclosed to any
third person or entity, any confidential or proprietary information without first obtaining the written consent of the responsible executive and the party concerned, if applicable, except if required to do so by law. 

The Executive may not make any statement to the media, as far as he is not authorized to do so by the responsible executive. 

  
 12 of 15 

 Employment Agreement 

 

  

	17.	 Third-Party Agreements 

The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which
restricts in any way the Executive’s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive’s engagement in any business. The Executive represents to the Company that the Executive’s
execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other
party. In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the
premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party. 

 
  

	18.	 Litigation 

During and after the Executive’s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution
of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii) the
investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive’s full cooperation in connection with such claims, actions or investigations shall
include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. 

During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any
investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. 

The Company shall reimburse the Executive for any reasonable
out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 18. 

  
 13 of 15 

 Employment Agreement 

 

  

	19.	 Miscellaneous 

 

	19.1.	 Entire Agreement 

This Employment Agreement constitutes the complete Employment Agreement between the Parties regarding its subject matter and supersedes all
prior oral and/or written agreements, representations and/or communications, concerning the subject matter hereof. 
  

	19.2.	 Amendments 

Any amendments or supplementation of this Employment Agreement shall require written form. The written form may be dispensed only in writing.

  

	19.3.	 Governing Law and Jurisdiction 

This Employment Agreement shall be construed in accordance with and governed by Swiss law (without giving effect to the principles of conflicts
of law). 
 Any dispute, controversy or claim arising out of or in connection with this Employment Agreement, including the validity,
invalidity, breach or termination thereof, and including tort claims, shall be exclusively submitted to and determined by the ordinary courts at the domicile of the defendant party or where the Executive normally performs his duties. 

 

	19.4.	 Execution 

The Parties have duly executed this Employment Agreement in two originals, each Party receiving one original. 

 
  

	20.	 Condition Precedent 

This Agreement will only come into effect if all necessary work permits have been granted by the local authorities and it will automatically
end with the expiration of such permits. 

  
 14 of 15 

 Employment Agreement 

 

			
	 Signatures
  
	  	 
	 Company
  
	  	 Monte Rosa Therapeutics AG

 

	Boston, 6/17/2021	  	/s/ Markus Warmuth
	Place, date	  	Markus Warmuth
		  	 Chief Executive Officer
  

	 Executive
  
	  	 
	Basel, Switzerland, 6/17/2021	  	/s/ John Castle
	Place, date	  	John Castle

  
 15 of 15EX-10.12

 Exhibit 10.12 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the
“Company”), and Filip Janku, MD, PhD (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration
statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this
Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the offer letter between the Executive and the Company dated April 27,
2021, as amended May 4, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement. 

WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the
new terms and conditions contained herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein
contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

1.    Employment. 

(a)    Term. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to
this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the provisions hereof (the “Term”). The Executive’s employment with the Company shall continue to be
“at will,” meaning that the Executive’s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement. 

(b)    Position and Duties. The Executive shall serve as the Chief Medical Officer of the Company and shall have
such powers and duties as may from time to time be prescribed by the Chief Executive Officer (the “CEO”) or other duly authorized executive. The Executive shall devote the Executive’s full working time and efforts to the
business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Company (the “Board”), or engage in religious,
charitable or other community activities as long as such services and activities do not interfere with the Executive’s performance of the Executive’s duties to the Company. 

(c)    Location. The Executive will initially work remotely in Texas. As a condition of the Executive’s
employment, the Executive is required to relocate his primary residence to the Boston, Massachusetts area no later than December 1, 2022. Following the Executive’s relocation to the Boston, Massachusetts area, his primary work location
will be the Company’s U.S. office, currently located in Boston, Massachusetts. At all times during the Executive’s employment, the Executive may be required to travel regularly for business, including international travel, consistent with
the Company’s business needs. 

 2.    Compensation and Related Matters. 

(a)    Base Salary. The Executive’s initial base salary shall be paid at the rate of $400,000 per year. The
Executive’s base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as
“Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executive officers. 

(b)    Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined
by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive compensation shall be 40 percent of the Executive’s Base Salary; provided that any incentive compensation for
calendar year 2021 will be prorated based on the commencement date of the Executive’s employment. The target annual incentive compensation in effect at any given time is referred to herein as the “Target Bonus.” The actual
amount of the Executive’s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates. Except as otherwise provided herein or as may be provided by the Board or the Compensation Committee, the Executive must
be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation. 

(c)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers; provided that the Pre-Relocation Travel Expenses (as defined below) will be subject to Section 2(g) below. 

(d)    Other Benefits. The Executive shall be eligible to participate in or receive benefits under the
Company’s employee benefit plans in effect from time to time, subject to the terms of such plans. 
 (e)    Paid
Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time. 

(f)    Equity. The equity awards held by the Executive shall continue to be governed by the terms and conditions of
the Company’s applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the “Equity Documents”); provided, however, and notwithstanding anything to
the contrary in the Equity Documents, in the event of a termination by the Company without Cause or by the Executive for Good Reason, in either event within the Change in Control Period (as such terms are defined below), all stock options and other
stock-based awards held by the Executive shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the Date of Termination (as defined below). 

  
 2 

 (g)    Relocation Assistance. The Company shall reimburse the
Executive for his reasonable business-related travel expenses between his primary residence in Texas and the Company’s Boston, Massachusetts office between the date on which his employment with the Company commences and the date that the
Executive relocates his primary residence to the Boston, Massachusetts area, which shall be no later than December 1, 2022, up to a cap of $50,000 (the “Pre-Relocation Travel Expenses”),
subject to the Executive’s prompt submission of receipts and other documentation that may be requested by the Company consistent with its expense policies and procedures in effect for its executive officers. The Executive is required to submit
such receipts and documentation on a monthly basis, and the Company will reimburse the Executive for the applicable Pre-Relocation Travel Expenses within 60 days after receiving such receipts and
documentation, subject to the terms of this Section 2(g). The Company shall comply with applicable tax law and any associated withholding and tax reporting obligations with respect to the reimbursement of the
Pre-Relocation Travel Expenses. 
 To assist with the relocation of the Executive’s primary
residence, the Company will reimburse the Executive up to $50,000 of his relocation expenses (the “Relocation Reimbursement”), following submission of appropriate documentation and subject to applicable deductions and withholdings,
on the first practicable payroll date in 2022 following the Executive’s relocation and submission of appropriate documentation. The Executive must remain employed on the date of payment in order to receive such Relocation Reimbursement. The
Executive agrees that if he resigns his employment other than for Good Reason or if the Company terminates his employment for Cause, in either event within one year following the Executive’s receipt of the Relocation Reimbursement, the
Executive will repay the Company the gross amount of the Relocation Reimbursement within 10 days following the Date of Termination. 

3.    Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement
under the following circumstances: 
 (a)    Death. The Executive’s employment hereunder shall terminate
upon death. 
 (b)    Disability. The Company may terminate the Executive’s employment if the Executive is
disabled and unable to perform or expected to be unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need
not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s
then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the
Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of
the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of
such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the 

  
 3 

 
Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with
Disabilities Act, 42 U.S.C. §12101 et seq. 
 (c)    Termination by the Company for Cause. The
Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean, as determined by the Company in good faith, any of the following: 

(i)    the Executive’s willful misconduct in connection with the performance of the Executive’s duties,
including, without limitation, misappropriation of funds or property of the Company other than the occasional, customary and de minimis use of Company property for personal purposes; 

(ii)    the Executive’s commission of acts satisfying the elements of (A) any felony or (B) a misdemeanor
involving moral turpitude, deceit, dishonesty, fraud or conduct by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company if the Executive was retained in the Executive’s position; 

(iii)    the Executive’s continued non-performance of the Executive’s
duties that has continued for more than 15 days following written notice of such non-performance; 

(iv)    a material breach by the Executive of the Restrictive Covenants Agreement or any other confidentiality,
assignment, noncompetition and/or nonsolicitation obligations; 
 (v)    a material violation by the Executive of the
Company’s lawful written employment policies; 
 (vi)    the Executive’s diversion of any business or
business opportunity of the Company for the benefit of any party other than the Company without the consent of the Company; or 

(vii)    the Executive’s failure to cooperate with an internal investigation or an investigation by regulatory or
law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to
cooperate or to produce documents or other materials in connection with such investigation. 
 (d)    Termination by
the Company without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a
termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause. 

(e)    Termination by the Executive. The Executive may terminate employment hereunder at any time for any reason,
including but not limited to, Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the
following events without the Executive’s consent (each, a “Good Reason Condition”): 

  
 4 

 (i)    a material diminution in the Executive’s
responsibilities, authority or duties; 
 (ii)    a material diminution in the Executive’s Base
Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management
employees of the Company; 
 (iii)    a material change in the geographic location of the principal
office of the Company to which the Executive is assigned, such that there is an increase of at least fifty (50) miles of driving distance to such location from the Executive’s principal residence as of such change; or 

(iv)    a material breach of this Agreement by the Company. 

The “Good Reason Process” consists of the following steps: 

(i)    the Executive reasonably determines in good faith that a Good Reason Condition has occurred; 

(ii)    the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition
within 60 days of the first occurrence of such condition; 
 (iii)    the Executive cooperates in good
faith with the Company’s efforts, for a period of not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition; 

(iv)    notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure
Period; and 
 (v)    the Executive terminates employment within 60 days after the end of the Cure
Period. 
 If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

4.    Matters related to Termination. 

(a)    Notice of Termination. Except for termination as specified in Section 3(a), any termination of the
Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall
mean a notice which shall indicate the specific termination provision in this Agreement relied upon. 

  
 5 

 (b)    Date of Termination. “Date of
Termination” shall mean: (i) if the Executive’s employment is terminated by death, the date of death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company
for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given
or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) other than for Good Reason, 30 days after the date on which a Notice of
Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the
foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this
Agreement. 
 (c)    Accrued Obligations. If the Executive’s employment with the Company is terminated for
any reason, the Company shall pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary earned through the Date of Termination; (ii) unpaid expense reimbursements (subject
to, and in accordance with, Section 2(c) of this Agreement); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or
provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Obligations”). 

(d)    Resignation of All Other Positions. To the extent applicable, the Executive shall be deemed to have resigned
from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive’s employment for any reason. The Executive shall execute any
documents in reasonable form as may be requested to confirm or effectuate any such resignations. 
 5.    Severance
Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period. If the Executive’s employment is terminated by the Company without Cause as provided in
Section 3(d), or the Executive terminates employment for Good Reason as provided in Section 3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the Accrued Obligations, and subject to
(i) the Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that
shall not release the Executive’s rights under this Agreement, a reaffirmation of all of the Executive’s Continuing Obligations (as defined below), and, in the Company’s sole discretion, a
one-year post-employment noncompetition agreement, and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the
“Separation Agreement”), and (ii) the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement), which shall include a seven
(7) business day revocation period: 

  
 6 

 (a)    the Company shall pay the Executive an amount equal to 12
months of the Executive’s Base Salary (the “Severance Amount”); provided that in the event the Executive is entitled to any payments pursuant to the Restrictive Covenants Agreement, the Severance Amount received in any
calendar year will be reduced by the amount the Executive is paid in the same such calendar year pursuant to the Restrictive Covenants Agreement (the “Restrictive Covenants Agreement Setoff”); and 

(b)    subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the
Executive’s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider or the COBRA provider a monthly
payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12 month anniversary of the
Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA;
provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation,
Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates; and 

(c)    notwithstanding anything to the contrary in any of the Equity Documents: the portion of all time-based stock
options and other stock-based awards subject solely to time-based vesting held by the Executive as of the Effective Date (the “Time-Based Equity Awards”) scheduled to vest in the 12 month period following the Date of Termination
shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (A) the Date of Termination or (B) the effective date of the Separation Agreement (the “Accelerated Vesting Date”);
provided that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive’s Time-Based Equity Awards that are subject to acceleration pursuant to this subsection that would
otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A) the effective date of the Separation Agreement (at which time acceleration will occur), or (B) the date that the Separation Agreement can no longer
become fully effective (at which time the unvested portion of the Executive’s Time-Based Equity Awards subject to acceleration pursuant to this subsection will be forfeited). Notwithstanding the foregoing, no additional vesting of the
Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date. With respect to any performance-based vesting equity award, such award shall continue to be governed in all respects by the
terms of the applicable equity award documents. 
 The amounts payable under Section 5, to the extent taxable, shall be paid out in substantially equal
installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in
one calendar year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”), shall begin to be paid in 

  
 7 

 
the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury
Regulation Section 1.409A-2(b)(2). 
 The Executive shall not be required to mitigate the amount of any
payments provided for under this Section 5 or Section 6 of this Agreement by seeking other employment, and no payment shall be offset or reduced by the amount of any compensation or benefits provided to the Executive in any subsequent
employment. 
 6.    Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for
Good Reason within the Change in Control Period. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive’s employment is terminated either (a) by
the Company without Cause as provided in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3(e), and (ii) the Date of Termination is on or within 12 months after the occurrence of the first event
constituting a Change in Control (such period, the “Change in Control Period”). These provisions shall terminate and be of no further force or effect after the Change in Control Period. 

(a)    If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or
the Executive terminates employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of a
general release of claims against the Company and all related persons and entities that shall not release the Executive’s rights under this Agreement (the “Release”) by the Executive and the Release becoming fully effective,
all within the time frame set forth in the Release but in no event more than 60 days after the Date of Termination: 

(i)    the Company shall pay the Executive a lump sum in cash in an amount equal to the sum of (A)
12 months of the Executive’s then-current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) one (1) times the Executive’s Target Bonus for the then-current year
(or the Executive’s Target Bonus in effect immediately prior to the Change in Control, if higher) (the “Change in Control Payment”); provided that the Change in Control Payment shall be reduced by the amount of the
Restrictive Covenants Agreement Setoff, if applicable; and 
 (ii)    subject to the Executive’s
copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment
equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Date of
Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA;
provided, however, that if the Company determines that it cannot pay such amounts to the group 

  
 8 

 
health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then
the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to tax-related deductions and
withholdings and paid on the Company’s regular payroll dates. 
 The amounts payable under this Section 6(a), to the extent taxable, shall be paid
or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the
extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of
such 60-day period. 
 (b)    Additional Limitation. 

(i)    Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section 280G of the Code, and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not
below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur
if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the
following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash
payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits;
provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1,
Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1,
Q&A-24(b) or (c). 
 (ii)    For purposes of this
Section 6(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the
Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the
determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of
such state and local taxes. 

  
 9 

 (iii)    The determination as to whether a reduction in
the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations
both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding
upon the Company and the Executive. 
 (c)    Definitions. For purposes of this Agreement, “Change in
Control” shall mean a “Sale Event” as defined in the Company’s 2021 Stock Option and Incentive Plan (as the same may be amended from time to time). 

7.    Section 409A. 

(a)    Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from
service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to
Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one
day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. 
 (b)    All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for
another benefit. 
 (c)    To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments
or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury
Regulation Section 1.409A-1(h). 

  
 10 

 (d)    The parties intend that this Agreement will be administered in
accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder
comply with Section 409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(e)    The Company makes no representation or warranty and shall have no liability to the Executive or any other person if
any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

8.    Continuing Obligations. 

(a)    Restrictive Covenants Agreement. The terms of the Employee Confidentiality, Assignment, Nonsolicitation and
Noncompetition Agreement, dated May 29, 2021 (the “Restrictive Covenants Agreement”), between the Company and the Executive, attached hereto as Exhibit A, continue to be in full force and effect. For purposes of this
Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be
referred to as the “Continuing Obligations.” 
 (b)    Third-Party Agreements and Rights. The
Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive’s use or disclosure of information, other than confidentiality
restrictions (if any), or the Executive’s engagement in any business. The Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the
Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive’s work for the Company, the Executive will not disclose or make use of any
information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of
non-public information belonging to or obtained from any such previous employment or other party. 

(c)    Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall
cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while
the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive’s full cooperation in
connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at

  
 11 

 
mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any
federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 8(c). 

(d)    Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company which
might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes
to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving
any actual damage to the Company. 
 9.    Consent to Jurisdiction. The parties hereby consent to the
jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to
service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. 

10.    Waiver of Jury Trial. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT
TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE
EXECUTIVE’S OR THE COMPANY’S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT. 

11.    Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, provided that the Restrictive Covenants Agreement and the Equity Documents remain in full force and effect.

 12.    Withholding; Tax Effect. All payments made by the Company to the Executive under this Agreement shall
be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect
associated with any payments or benefits or for any deduction or withholding from any payment or benefit. 

13.    Assignment; Successors and Assigns. Neither the Executive nor the Company may make any assignment of this
Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive
Covenants Agreement) without the Executive’s consent to any affiliate or to any person or entity with 

  
 12 

 
whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided,
further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting
pursuant to Section 2(f), Section 5 or Section 6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the
Executive’s and the Company’s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive’s death after the Executive’s termination of employment but prior to the completion by the
Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to the Executive’s death (or to the Executive’s
estate, if the Executive fails to make such designation). 
 14.    Enforceability. If any portion or provision
of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the
application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the
fullest extent permitted by law. 
 15.    Survival. For the avoidance of doubt, this Agreement shall survive the
termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein. 

16.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. 
 17.    Notices. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. 

18.    Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive
and by a duly authorized representative of the Company. 
 19.    Effect on Other Plans and Agreements. An
election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company’s benefit
plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company’s benefit plans, programs or policies except as otherwise provided in Section 8 hereof, and except that the
Executive shall 

  
 13 

 
have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. Except for the Restrictive Covenants Agreement, in the event that the Executive is party
to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both.
Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement. 

20.    Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects
by the laws of the Commonwealth of Massachusetts without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be
interpreted and applied by the United States Court of Appeals for the First Circuit. 
 21.    Counterparts. This
Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

[Signature page follows] 

  
 14 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. 
  

			
	MONTE ROSA THERAPEUTICS, INC.
		
	By:	 	 /s/ Markus Warmuth

	Its:	 	Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ Filip Janku

	Filip Janku, MD, PhD

 Exhibit A 

Restrictive Covenants Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]